cerca CERCA
Domenica 07 Marzo 2021
Aggiornato: 03:13
Temi caldi

Winhealth Pharma

Winhealth Pharma and TWiB Enter into Strategic Licensing Partnership on AC-203

SHANGHAI and TAIPEI, Jan. 7, 2021 /PRNewswire/ -- Hongkong Winhealth Pharma Group (Winhealth Pharma) and Taiwan TWi Biotechnology, Inc. (TWiB) announced strategic partnership granting Winhealth Pharma exclusive right to develop and commercialize rare disease asset AC-203 in mainland China, Hong Kong and Macao for indications including hereditary epidermolysis bullosa (EB), bullous pemphigoid and other skin diseases.

ora in
Prima pagina
in Evidenza